- Home
- BMN vs CHRS Comparison
BMN vs CHRS Comparison
Compare BMN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMN
- CHRS
- Stock Information
- Founded
- BMN 2020
- CHRS 2010
- Country
- BMN United States
- CHRS United States
- Employees
- BMN 19800
- CHRS N/A
- Industry
- BMN Trusts Except Educational Religious and Charitable
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMN Finance
- CHRS Health Care
- Exchange
- BMN Nasdaq
- CHRS Nasdaq
- Market Cap
- BMN 155.1M
- CHRS 156.0M
- IPO Year
- BMN N/A
- CHRS 2014
- Fundamental
- Price
- BMN $25.11
- CHRS $1.06
- Analyst Decision
- BMN
- CHRS Buy
- Analyst Count
- BMN 0
- CHRS 6
- Target Price
- BMN N/A
- CHRS $7.10
- AVG Volume (30 Days)
- BMN 29.9K
- CHRS 1.6M
- Earning Date
- BMN 01-01-0001
- CHRS 11-04-2024
- Dividend Yield
- BMN 4.66%
- CHRS N/A
- EPS Growth
- BMN N/A
- CHRS N/A
- EPS
- BMN N/A
- CHRS N/A
- Revenue
- BMN N/A
- CHRS $308,134,000.00
- Revenue This Year
- BMN N/A
- CHRS $6.15
- Revenue Next Year
- BMN N/A
- CHRS $15.04
- P/E Ratio
- BMN N/A
- CHRS N/A
- Revenue Growth
- BMN N/A
- CHRS 69.37
- 52 Week Low
- BMN $21.51
- CHRS $1.20
- 52 Week High
- BMN $25.59
- CHRS $4.97
- Technical
- Relative Strength Index (RSI)
- BMN 55.52
- CHRS 39.59
- Support Level
- BMN $24.99
- CHRS $1.26
- Resistance Level
- BMN $25.18
- CHRS $1.37
- Average True Range (ATR)
- BMN 0.20
- CHRS 0.09
- MACD
- BMN -0.01
- CHRS -0.00
- Stochastic Oscillator
- BMN 33.96
- CHRS 3.33
About BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest
BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.